Experimental Pathology Laboratory (EPL)

$1,046,607ZICFY2025CANIH

Division Of Basic Sciences - Nci

Investigators

Linked publications, trials & patents

Paper 38918394 Paper 38912586 Paper 38897168 Paper 38709562 Paper 38398178 Paper 38230434 Paper 37725716 Paper 37224815 Paper 37205196 Paper 37169743 Paper 37090576 Paper 37090574 Paper 37031249 Paper 36963628 Paper 36932076 Paper 36869703 Paper 36790955 Paper 36754451 Paper 36715552 Paper 36695611 Paper 35816430 Paper 35699495 Paper 35383277 Paper 35351966 Paper 35262093 Paper 35034369 Paper 34811556 Paper 34255745 Paper 34253580 Paper 34195677 Paper 34071938 Paper 33851061 Paper 33834359 Paper 33767405 Paper 33536203 Paper 33526872 Paper 33481911 Paper 33129371 Paper 33103210 Paper 32936035 Paper 32835732 Paper 32762616 Paper 32637350 Paper 32502310 Paper 32483558 Paper 32367248 Paper 32316112 Paper 32107047 Paper 32068253 Paper 31949145 Paper 31911546 Paper 31864026 Paper 31527799 Paper 29956066 Paper 29925955 Paper 29700408 Paper 29548022 Paper 29492969 Paper 29472714 Paper 29457738 Paper 29443622 Paper 29437706 Paper 29307568 Paper 29125916 Paper 29024776 Paper 28347266 Paper 28339906 Paper 27548802 Paper 27221702 Paper 27177816 Paper 27154171 Paper 26337566 Paper 26044002 Paper 26043998 Paper 26022333 Paper 25870121 Paper 25838812 Paper 25774315 Paper 25763314 Paper 25636426 Paper 25023613 Paper 24883046 Paper 24809843 Paper 24487999

Abstract

The Experimental Pathology Laboratory (EPL) provides histopathology support across a large number of collaborators within the Centers for Cancer Research, as well as ongoing support to studies that include investigators in DCEG, NCI, as well as multi-institute collaborations between NCI and other NIH institutes. The EPL has provided a diversity of services, including tissue microarray (TMA) construction, development and deployment of immunohistochemical assays, tissue fixation, processing, embedding and microtomy, as well as whole slide imaging. Additional support included in situ assays for RNA and DNA, digital droplet PCR and image analysis. Sectioning and staining of frozen tissue is offered, and pathology interpretation of results, including scoring of immunohistochemical stains are provided. Over the last reporting period, the laboratory has directly contributed to nine publications. The time frame from the support provided by the EPL can vary from months to over 5 years, as some projects are in the final phases, for which the EPL provides the critical last elements of data. Other projects are foundational, including the construction of TMAs for which extensive effort may be devoted in screening samples and construction of the TMA, for which publication of the effort may be 2 or more years later. However in many instances, these projects will continue to contribute value for over a decade. The outcome of task conducted in the EPL is diverse. Recent studies have included screening the expression patterns of potential cancer antigens, in support of new CAR-T and Antibody-based therapeutics. Other efforts include the confirmation of expression of potential biomarkers of cancer prognosis by immunohistochemistry. The detection of glycoproteins by means of immunohistrochemistry, in the context of cancer antigens or therapeutic targeting has become a critical portion of the EPLs contribution to CCR investigators. Evaluation of the relationships of immune-cell populations their regulatory interplay is carried out with immunohistochemistry and image analysis.

View original record on NIH RePORTER →